Feraheme® (ferumoxytol)

Feraheme (ferumoxytol) is covered for adults (≥18) for FDA‑approved uses—iron deficiency anemia intolerant/unresponsive to oral iron and CKD‑related anemia—and for one compendial off‑label use (iron deficiency in heart failure); patients under 18 are excluded. Approvals require documentation of diagnosis and age, specialist prescribing/consultation for CKD (nephrologist/hematologist) and heart failure (cardiologist/hematologist), meeting prior‑therapy/clinical criteria for “other” iron deficiency (failed/intolerant oral iron, malabsorption, current ESA therapy, or cancer/chemotherapy‑related anemia), adherence to the two‑dose IV regimen (510 mg then 510 mg in 3–8 days), applicable safety criteria, and are authorized for up to 12 months.

"Treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron (FDA-approved)"